Pay in 4 interest-free payments of $7.19 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Key findings relevant to nausea included: Nausea was most prevalent during the dose-escalation phase and tended to diminish over time as participants adapted to the medication Higher doses were associated with higher rates of nausea and vomiting The majority of gastrointestinal events were transient and self-limiting Discontinuation due to gastrointestinal side effects occurred in a small but notable proportion of participants, particularly in higher-dose groups It should be noted that the weight-loss outcomes described above are from a Phase 2 trial and cannot be directly compared with those of licensed medicines without head-to-head data
The provider's assessment, not the lab morphology, determines whether D50.x or D56.x applies
(2012) 14:R62
Several immunobiotic probiotics, including strains of L
Importance of IL-10 modulation by probiotic microorganisms in gastrointestinal inflammatory diseases
US$ 28.13
US$ 23.46
US$ 24.80
US$ 24.01
US$ 27.20
US$ 27.81
US$ 25.48
US$ 28.89
US$ 25.79
US$ 29.76
